These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33376383)

  • 1. Screening and Identifying Cisplatin-Related Gene Mutations in Lung Squamous Cell Carcinoma.
    Li X; Wang Y; Hu S; Bai Y
    Pharmgenomics Pers Med; 2020; 13():757-766. PubMed ID: 33376383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma.
    Li R; Liu J; Fang Z; Liang Z; Chen X
    Front Pharmacol; 2020; 11():572627. PubMed ID: 33192515
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of a prognostic gene signature in patients with cisplatin resistant squamous cell lung cancer.
    Mu Y; Dong Y; Zheng M; Barr MP; Roviello G; Hu Z; Liu J
    J Thorac Dis; 2024 Jul; 16(7):4567-4583. PubMed ID: 39144297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
    Diao X; Guo C; Liu L; Wang G; Li S
    Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
    Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the
    Zou S; Ye J; Hu S; Wei Y; Xu J
    Int J Gen Med; 2022; 15():19-31. PubMed ID: 35018111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
    Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
    Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
    Huang G; Zhang J; Gong L; Huang Y; Liu D
    BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
    Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
    Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic analysis identifies three-lncRNA signature as a potentially prognostic biomarker for lung squamous cell carcinoma using bioinformatics strategy.
    Hu J; Xu L; Shou T; Chen Q
    Transl Lung Cancer Res; 2019 Oct; 8(5):614-635. PubMed ID: 31737498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis.
    Zhao X; Wang J; Zhu R; Zhang J; Zhang Y
    Sci Rep; 2021 Oct; 11(1):21014. PubMed ID: 34697393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy.
    Qiang H; Li J; Chang Q; Shen Y; Qian J; Chu T
    Front Oncol; 2022; 12():835225. PubMed ID: 35211415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
    Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
    PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of seven-gene signature for prediction of lung squamous cell carcinoma.
    Wang Z; Wang Z; Niu X; Liu J; Wang Z; Chen L; Qin B
    Onco Targets Ther; 2019; 12():5979-5988. PubMed ID: 31440059
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive Analysis of Immune Implication and Prognostic Value of
    Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
    Front Oncol; 2021; 11():798425. PubMed ID: 35047409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Lung Squamous Carcinoma.
    Zhai WY; Duan FF; Chen S; Wang JY; Zhao ZR; Wang YZ; Rao BY; Lin YB; Long H
    Front Cell Dev Biol; 2022; 10():770550. PubMed ID: 35300428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis of competing endogenous RNA network revealing lncRNAs as potential prognostic biomarkers in human lung squamous cell carcinoma.
    Sui J; Xu SY; Han J; Yang SR; Li CY; Yin LH; Pu YP; Liang GY
    Oncotarget; 2017 Sep; 8(39):65997-66018. PubMed ID: 29029488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database.
    Ke D; Guo Q; Fan TY; Xiao X
    Cancer Biother Radiopharm; 2021 Apr; 36(3):280-291. PubMed ID: 33112657
    [No Abstract]   [Full Text] [Related]  

  • 20. Integrative analysis of genomic alteration, immune cells infiltration and prognosis of lung squamous cell carcinoma (LUSC) to identify smoking-related biomarkers.
    Li J; Li H; Zhang C; Zhang C; Wang H
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107053. PubMed ID: 33045568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.